CAC Software vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CAC Software

by 4DMedical (Imbio CAC Software)

ElucidVivo A.3

by Elucid

AI Verdict

Tool A specializes in quantifying coronary artery calcification from non-contrast CTs for cardiovascular risk assessment. Tool B offers a more comprehensive analysis of arterial plaque composition and stability, including calcifications, from CT angiography, aiding in atherosclerosis patient stratification and treatment decisions. While both contribute to cardiovascular care through AI-powered CT analysis, Tool A focuses narrowly on calcification, whereas Tool B provides a broader, more detailed plaque characterization.

Choose CAC Software if…

Choose Imbio's CAC Software if your primary goal is to quickly and automatically quantify coronary artery calcification from existing non-contrast chest CT scans. This tool is ideal for initial cardiovascular risk assessment, providing key metrics like the Agatston score to help identify patients at risk for coronary artery disease.

View CAC Software →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require a detailed, quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients and optimize treatment decisions. This system is particularly useful when precise measurements of plaque components like Lipid-Rich Necrotic Core (LRNC) and derived FFRct are critical for advanced clinical management.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CAC Software	ElucidVivo A.3
Deployment	Cloud-based (SaaS), integrates with PACS	Cloud and on-premise secure deployment.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CAC Software

Tool A (CAC Software) emphasizes fully automated processing with no user input or intervention, seamlessly integrating into existing DICOM viewing workflows and delivering results as DICOM or PDF reports. This 'no-touch' approach suggests a highly streamlined and efficient user experience for routine coronary artery calcification scoring. While Tool B offers interactive visualizations, Tool A's automation minimizes workflow disruption.

Clinical Value

ElucidVivo A.3

Tool B (ElucidVivo A.3) offers a more advanced and comprehensive clinical assessment by providing quantitative analysis of arterial plaque composition and stability, including Lipid-Rich Necrotic Core (LRNC) and deriving fractional flow reserve (FFRct). This deeper insight into atherosclerosis, validated against histology, has demonstrated a 40% improvement in predictive accuracy for major adverse neurologic events compared to stenosis alone.

Pricing & Value

Tie

Both Tool A and Tool B explicitly state 'contact for pricing' on their respective platforms and related comparison sites. Without transparent, publicly available pricing information or detailed cost-benefit analyses, it is not possible to determine which tool offers better value.

Enterprise Readiness

CAC Software

Tool A (CAC Software) explicitly states HIPAA compliance and offers a Business Associate Agreement (BAA), which are crucial for healthcare enterprise adoption. Furthermore, it provides flexible deployment options including cloud, on-premise, and through various partner platforms. Tool B's BAA and HIPAA compliance are only implied, and its deployment options are less explicitly detailed.

Innovation

ElucidVivo A.3

Tool B (ElucidVivo A.3) demonstrates greater innovation by moving beyond standard calcification scoring to provide detailed, histology-validated quantitative analysis of arterial plaque composition and stability, including the derivation of FFRct. This offers unprecedented depth of insight into atherosclerosis for patient stratification and treatment optimization, representing a more profound advancement in clinical understanding.

Support & Docs

CAC Software

Imbio, the company behind Tool A, explicitly states that it offers 24/7/365 customer support via phone and email. They also mention that user manuals and other product documentation can be requested through their support channels. Tool B's public information does not detail its support hours or the immediate availability of comprehensive documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CAC Software	ElucidVivo A.3
Name	CAC Software	ElucidVivo A.3
Company	Imbio	Elucid Bioimaging
Primary Analysis Focus	Automated image post-processing for coronary artery calcification quantification from non-contrast chest CT.	Quantitative analysis of arterial plaque composition and stability from CT angiography.
Key Output Metrics/Analysis	Agatston score, arterial age, calcified lesion mass and volume, 3D visualizations and annotated images.	Quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications; lesion-level plaque composition visualization; 3D visualization of highlighted vessels; fractional flow reserve (FFRct).
Input Imaging Modality	Non-contrast, chest computed tomography (CT)	CT angiography
Specialties Supported	Cardiology, Radiology	Cardiology, Radiology, Vascular Surgery
Validation/Basis	Deep-learning based analysis	Validated on ground-truth histology

Videos

Demos, reviews, and walkthroughs featuring CAC Software and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What type of imaging study is required for each tool?

Imbio's Coronary Artery Calcification (CAC) software analyzes non-contrast chest CT scans to determine the location and amount of calcification within the coronary arteries. ElucidVivo A.3 by Elucid Bioimaging provides quantitative analysis of arterial plaque composition and stability from CT angiography.

What are the primary clinical insights and applications offered by each tool?

Imbio CAC Software focuses on quantifying coronary artery calcification to aid in risk assessment for coronary artery disease, providing metrics like Agatston score and arterial age. ElucidVivo A.3 provides detailed quantitative analysis of arterial plaque composition and stability, including Lipid-Rich Necrotic Core (LRNC) and matrix, to assist in atherosclerosis patient stratification and optimize treatment decisions.

What specific quantitative metrics do these tools provide to aid in diagnosis and treatment planning?

Imbio CAC Software outputs the Agatston score, arterial age, calcified lesion mass, and volume. ElucidVivo A.3 objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, and also derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.

How do these tools differ in their approach to assessing cardiovascular risk and disease progression?

Imbio CAC Software assesses cardiovascular risk by quantifying the presence and extent of coronary artery calcification from non-contrast CTs. ElucidVivo A.3 offers a more in-depth analysis of arterial plaque *composition* and *stability* from CT angiography, which is crucial for stratifying patients with atherosclerosis and optimizing treatment decisions.

What is the validation basis for each tool's analysis?

Both tools are FDA-cleared. ElucidVivo A.3 explicitly states its plaque characteristics measurements are validated against ground-truth histology. Imbio CAC Software's validation involves evaluating cardiovascular disease risk category agreement between its analysis and ground truth, achieving a Cohen's kappa of 0.907 for a 5-category risk assessment.